Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Laboratoire HRA Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011798
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laboratoire HRA Pharma (HRA Pharma) is a healthcare products provider that offers women’s health and endocrinology products. The company offers a wide range of women’s health products which include emergency contraception, uterine fibroids, regular contraception and genital herp products among others. Its endocrinology products comprise advanced adrenal cortical carcinoma and cushing’s syndrome medicines; and lysosafe service devices. The company operates through partnerships with pharmaceutical companies, public and private institutions, healthcare professionals and others. It operates in France, Germany, Ireland, Italy, Switzerland, Spain, Portugal, Belgium and the UK. HRA Pharma is headquartered in Paris, France.

Laboratoire HRA Pharma SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Venture Financing 13
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Private Equity 14
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
Partnerships 17
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
Licensing Agreements 18
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Asset Transactions 22
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS – Key Competitors 23
Laboratoire HRA Pharma SAS – Key Employees 24
Laboratoire HRA Pharma SAS – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Jul 12, 2016: HRA Pharma Announces CEO Transition to Position Company for the Next Phase of Growth 27
Product News 28
11/21/2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment 28
01/20/2016: Depression experts question effectiveness of stress hormone drug 29
Clinical Trials 31
Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 31
Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City 33
May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Key Facts 2
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS, Key Competitors 23
Laboratoire HRA Pharma SAS, Key Employees 24
Laboratoire HRA Pharma SAS, Other Locations 25
Laboratoire HRA Pharma SAS, Subsidiaries 25

★海外企業調査レポート[Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DISH Network Corporation:企業の戦略・SWOT・財務情報
    DISH Network Corporation - Strategy, SWOT and Corporate Finance Report Summary DISH Network Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • IntraPace Inc:医療機器:M&Aディール及び事業提携情報
    Summary IntraPace Inc (IntraPace) is a medical device company that develops novel implantable systems. The company offers abiliti systems that contain sensors intended to track consumption events and physical activity to direct when therapy is delivered and to monitor a patient's progress toward wei …
  • Boustead Heavy Industries Corp Bhd:企業の戦略・SWOT・財務分析
    Boustead Heavy Industries Corp Bhd - Strategy, SWOT and Corporate Finance Report Summary Boustead Heavy Industries Corp Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • China Resources Power Holdings Co Ltd:発電所・企業SWOT分析
    China Resources Power Holdings Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Four Seasons Hotels Ltd:企業の戦略・SWOT・財務情報
    Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Wellcome Trust Sanger Institute:医療機器:M&Aディール及び事業提携情報
    Summary Wellcome Trust Sanger Institute (Sanger Institute) a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research a …
  • Sally Beauty Holdings Inc:企業の戦略・SWOT・財務分析
    Sally Beauty Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sally Beauty Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Factor Therapeutics Ltd (FTT):企業の財務・戦略的SWOT分析
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd, is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor …
  • Fubon Insurance Co., Ltd.:企業の戦略的SWOT分析
    Fubon Insurance Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Repsol SA (Repsol) is an integrated oil and gas company. It has presence across the entire value chain: exploration and production, transformation, development and marketing of energy. The company’s upstre …
  • Xinjiang Goldwind Science & Technology Co Ltd (002202):企業の財務・戦略的SWOT分析
    Xinjiang Goldwind Science & Technology Co Ltd (002202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Domino’s Pizza, Inc.:企業の戦略・SWOT・財務分析
    Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report Summary Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Noevir Holdings Co Ltd (4928):企業の財務・戦略的SWOT分析
    Noevir Holdings Co Ltd (4928) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Histogen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Histogen Inc (Histogen) is a regenerative medicine company that develops novel therapies. The company offers research and develops cell based products. Its products include insoluble human extracellular matrix and a soluble complex of proteins. Histogen’s proprietary technologies are used in …
  • Analytik Jena AG:医療機器:M&Aディール及び事業提携情報
    Summary Analytik Jena AG (Analytik Jena), a subsidiary of Endress+Hauser AG is a provider of instruments and products for analytical measuring technology and life science. The company’s major products include atomic spectrometers, optical emission spectroscopy devices, mass spectrometers, mercury an …
  • OriGene Technologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and markets genome research and diagnostic products. OriGene provides products such as qPCR r …
  • Arrowhead Pharmaceuticals Inc (ARWR):企業の財務・戦略的SWOT分析
    Summary Arrowhead Pharmaceuticals Inc (Arrowhead), formerly known as Arrowhead Research Corp, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and AR …
  • Bone Solutions Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bone Solutions Inc (BSI) is a medical device company that provides orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It provides osteocrete bone graft substitute that offers adhere ligaments and tendons …
  • Mississippi Power Co:企業の戦略的SWOT分析
    Mississippi Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Ascent Resources plc (AST):企業の財務・戦略的SWOT分析
    Ascent Resources plc (AST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆